Navigation Links
Medarex Announces Completion of Sale of Shares in Genmab A/S
Date:2/1/2008

PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it has completed the sale of approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 1, 2008. Medarex expects to receive approximately $151.8 million (USD) in net proceeds from the sale. The sale of Genmab shares reduces Medarex's ownership in Genmab to approximately 5.1 percent.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
2. Medarex Announces Election of Marc Rubin as New Board Member
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
6. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
7. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
8. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
9. Rigel Announces Pricing of Public Offering of Common Stock
10. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008
11. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from ... three key industry events beginning with Patient-Centered Clinical Trials ... in Boston , September 4-5. Patient recruitment ... and Aaron Fleishman will share insights on the ... a variety of tactics – from media to mobile apps ...
(Date:8/28/2014)... new work by a Florida State University research team ... take your temperature, emit white light, and convert photon ... looks like a butterfly. , Biwu Ma, associate professor ... the FAMU-FSU College of Engineering, created the molecule in ... to discover that his creation has many other unique ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... LINCOLN, Neb., Aug. 20 LI-COR announces its second,webinar ... in In Vivo Imaging: Near Infrared Optical Imaging of ... CDT., Near-infrared (NIR) fluorescence offers dramatic benefits for ... depth of penetration and,decreased autofluorescence and light scatter that ...
... 20 MedPredict, a global,provider of pharmaceutical competitive ... providing critical strategic insight for pharma,and biotech companies ... sclerosis,(MS) therapies., Biogen/Elan,s Tysabri has been under ... a rare and potentially fatal brain disease,associated with ...
... Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets ... today that all pharmaceutical,intellectual property will be sold at ... of the pieces of intellectual property for sale is ... of a,branded drug that currently has more than $2 ...
Cached Biology Technology:LI-COR August 27th On-Line Webinar Introduces New Approach to Small Animal In Vivo Imaging 2Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri 2Spherics, Inc. Successful Bidder May Make MHRA Submission 2
(Date:8/28/2014)... Research Careers) Program has announced the travel award recipients ... 18 22, 2014 in San Diego, California. ... students, post doctorates and scientists from underrepresented groups into ... encourage the participation of young scientists at the American ... 16 awards totaling $29,600., The FASEB MARC Program is ...
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... Durham, NC The most toxic, brightly colored members of ... says a new study. So-named because some tribes use ... frogs of the Amazon jungle are well known for their ... forest frogs serve to broadcast their built-in chemical weapons: ...
... project to develop and evaluate new tools to control ... a five year, 12 million project involving sixteen partners ... Seventh Framework programme. Because malaria is transmitted by ... disease. Wide scale use of insecticides on bednets ...
... laboratory discoveries into daily clinical practice is important, but ... to the laboratory, to further explore and explain clinically ... basic researchers to understand and address clinical challenges and ... integrate and use new technologies. The key towards ...
Cached Biology News:Fitness tests for frogs? 2€12 million ($16.9 million) project to develop new tools for malaria control 2
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
... Alkaline Phosphatase, Calf Intestinal (CIAP), catalyzes ... RNA, and ribo- and deoxyribonucleoside triphosphates. This ... religation of linearized cloning vector DNA by ... may also be used for the dephosphorylation ...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@...
Biology Products: